The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine.

The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine.

Some patients with hyperprolactinaemia are unable to tolerate even low doses of oral bromocriptine. In such cases, it is difficult to predict whether serum prolactin might be normalized if higher doses could be tolerated, or whether true resistance to bromocriptine is present. We have investigated 8...

Bibliografske podrobnosti
Main Authors:	Grossman, A, Wass, J, Besser, M
Format:	Journal article
Jezik:	English
Izdano:	1987

Podobne knjige/članki

Depot-bromocriptine treatment for prolactinomas and acromegaly.
od: Grossman, A, et al.
Izdano: (1986)

DEPOT BROMOCRIPTINE IN THE TREATMENT OF PROLACTINOMAS AND ACROMEGALY
od: Grossman, A, et al.
Izdano: (1985)

Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine.
od: Ciccarelli, E, et al.
Izdano: (1988)

Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
od: Verhelst, J, et al.
Izdano: (1991)

Oral prednisolone supplement abolishes the acute adverse effects following initiation of depot bromocriptine therapy.
od: Jenkins, P, et al.
Izdano: (1996)

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine
od: Marianne F. Clausen, et al.
Izdano: (2021-12-01)

The effect of dopamine agonist therapy on large functionless pituitary tumours.
od: Grossman, A, et al.
Izdano: (1985)

The outcome of macroprolactinomas resistant to dopamine agonists
od: Coculescu, M, et al.
Izdano: (2005)

Bromocriptine, a Dopamine (D2 ) Receptor Agonist, Used Alone and in Combination with Glipizide in Sub–Therapeutic Doses to Ameliorate Hyperglycaemia
od: Harish Kumar V.S., et al.
Izdano: (2013-09-01)

Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2
od: O A Gerasimenko, et al.
Izdano: (2011-12-01)

Two new dopamine agonists that are long acting in vivo but short acting in vitro.
od: Grossman, A, et al.
Izdano: (1980)

Bromocriptine and insulin sensitivity in lean and obese subjects
od: L Bahler, et al.
Izdano: (2016-11-01)

A bromocriptine-responsive corticotroph adenoma secreting alpha-MSH in a patient with Cushing's disease.
od: Hale, A, et al.
Izdano: (1988)

Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?
od: Turner, H, et al.
Izdano: (1999)

Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes
od: G. Tavares, et al.
Izdano: (2021-09-01)

Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia.
od: Ciccarelli, E, et al.
Izdano: (1989)

PROLACTINOMA IN A PREPUBERTAL CHILD - RESPONSE TO SURGERY, RADIOTHERAPY AND DOPAMINE AGONIST THERAPY
od: Sinn, D, et al.
Izdano: (1985)

Cabergoline or bromocriptine for prolactinoma?
od: Nicolás Triantafilo, et al.
Izdano: (2016-09-01)

A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome.
od: Newell-Price, J, et al.
Izdano: (1995)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
od: Michael A Via, et al.
Izdano: (2010-03-01)

Predictors of dopamine agonist resistance in prolactinoma patients
od: Elle Vermeulen, et al.
Izdano: (2020-05-01)

Central Hyperthermia Treated with Bromocriptine
od: P. Natteru, et al.
Izdano: (2017-01-01)

Bromocriptine in the Management of Central Hyperthermia
od: Krishnaprasad Narayanankutty, et al.
Izdano: (2024-08-01)

Repurposing of Bromocriptine for Cancer Therapy
od: Ean-Jeong Seo, et al.
Izdano: (2018-10-01)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
od: Via MA
Izdano: (2010-03-01)

Two new dopamine agonists that are long acting in vivo but short acting in vitro
od: Grossman, A, et al.
Izdano: (1980)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
od: Claudia Pivonello, et al.
Izdano: (2022-01-01)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
od: Xiaoshuang Liu, et al.
Izdano: (2019-01-01)

Dopamine agonist and tamoxifen combination therapy for a prolactin-secreting pituitary tumor resistant to dopamine agonist monotherapy: Case report and review
od: Zachary K. Christian, et al.
Izdano: (2020-09-01)

Bromocriptine in type 2 diabetes mellitus
od: C Shivaprasad, et al.
Izdano: (2011-01-01)

Bromocriptine for type 2 diabetes mellitus
od: Ooi, Cheow Peng, et al.
Izdano: (2013)

Clinical development of the GnRH agonist leuprolide acetate depot
od: Kristof Chwalisz, M.D., Ph.D.
Izdano: (2023-06-01)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
od: Jenkins, P, et al.
Izdano: (2000)

Dopamine Agonists and Pathologic Behaviors
od: Brendan J. Kelley, et al.
Izdano: (2012-01-01)

Bromocriptine use is associated with decreased smoking rates.
od: Murphy, M, et al.
Izdano: (2002)

Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
od: Barber, T, et al.
Izdano: (2011)

The participation of hypothalamic dopamine in morphine-induced prolactin release in man.
od: Delitala, G, et al.
Izdano: (1983)

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
od: Ismail, I.S., et al.
Izdano: (1994)

EFFECT OF OXYTOCIN AND BROMOCRIPTINE ON CORPORA LUTEA AND PSEUDOPREGNANCY IN MICE
od: N. A. S. AL- Khadi, et al.
Izdano: (1990-12-01)

A peripartum cardiomyopathy case treated with bromocriptine
od: Dilek Yeşilbursa, et al.
Izdano: (2021-03-01)